Axogen Q2 revenue $38.2M (+11% YoY); net loss narrows to $6.7M

Axogen, Inc.

2023-Q2 EPS reported -$0.32 revenue$74,819,000

Revenue $38.2M in Q2 2023, up 11% vs Q2 2022; scheduled procedures grew >20%, trauma low-single-digit.
Net loss $6.7M ($0.16 per share) vs $7.7M loss a year ago; adjusted net loss $1.3M ($0.03 per share).
Gross margin 81.1% (vs 81.8% YoY); cash & investments $40.8M; $3.6M capex for new Dayton processing facility.
FY 2023 revenue guidance maintained at $154M-$159M (11-15% growth); gross margin expected ~80% for full year.
Pilot launched Axoguard HA+ Nerve Protector; BLA submission for Avance expected Q1-Q2 2024 with target approval H1 2025.

item 2.02 item 7.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.7

Axogen, Inc. updated its six months ended June 30, 2023 guidance (reaffirmed).

Period: six months ended June 30, 2023
Guidance: reaffirmed
Result: reported results

Exact text from the filing

On July 26, 2023, Axogen, Inc. (the “Company”) issued a press release announcing its three and six months ended June 30, 2023 financial results.

View on SEC.gov

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Axogen, Inc. reported second quarter ended June 30, 2023 results: revenue $38.2 million, net income $6.7 million, EPS $0.16 per share. Guidance reaffirmed.

Period: second quarter ended June 30, 2023
Revenue: $38.2 million
Net income: $6.7 million
EPS: $0.16 per share
Guidance: reaffirmed
Result: reported results

Exact text from the filing

today reported financial results and business highlights for the second quarter ended June 30, 2023. Second Quarter Financial Results and Business Highlights • Revenue was $38.2 million during the second quarter, an increase of approximately 11% over the second quarter of 2022. • The Company estimates that revenues from scheduled non-trauma procedures

View on SEC.gov

Browse all earnings releases →

Axogen, Inc. filing history →

Source: SEC EDGAR

accession 0000805928-23-000087

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.